Our Vision : To become a leading specialty biopharmaceutical company in reproductive medicine. PregLem has IP rights on "first in class" compounds which are in clinical and pre-clinical development. At PregLem, we value collaborations with academic units innovating in reproductive medicine
PregLem SA ▫ Chemin des Aulx 12 ▫ 1228 Plan-les-Ouates, Geneva ▫ Switzerland
T +41 (0)22 884 03 40 ▫ F +41 (0) 22 884 03 49 ▫ info@preglem.com
T +41 (0)22 884 03 40 ▫ F +41 (0) 22 884 03 49 ▫ info@preglem.com
Latest News
11.08.2010
PREGLEM ANNOUNCES IN-LICENSING DEAL WITH MERCK SERONO FOR
POST-OPERATIVE ADHESIONS & ENDOMETRIOSIS
03.06.2010
PREGLEM ANNOUNCES POSITIVE RESULTS FOR ESMYA SECOND PHASE III. PREPARING FOR SUBMISSION TO THE EMA IN 2010
> Read all the news